MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
→
Sort
Language
Type
Field
Venue
Journal of Clinical Oncology
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

9,514 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
9,514 works in the cohort · of 4,299,418page 92 of 191

Labels cover 106 of 9,514 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 9,514 of 9,514 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Is Seeing Believing?
Michael Brundage
2010· letter· en· Journal of Clinical Oncology· Health Professions
machine prediction:candidate · noneconsensus · none
2
citations
affgemma · no categorygpt · no categorymodels agree
The diverse genomic landscape of low-risk prostate cancer.
Matthew R. Cooperberg, Nicholas Erho, June M. Chan, Felix Y. Feng, Janet E. Cowan, Kaye Ong +10 more
2017· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
aboutno affunlabeled
Radiotherapy and Hodgkin's Lymphoma
Prajnan Das, Chul S. Ha, James D. Cox
2005· letter· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affunlabeled
Clinical and molecular characteristics of early progressors (EPs) and long-term progression-free survivors (LTPs) from the phase 3 ADRIATIC trial of consolidation durvalumab (D) vs placebo (P) after concurrent chemoradiotherapy (cCRT) in limited-stage small-cell lung cancer (LS-SCLC).
David A. Barbie, Mingchao Xie, Maria A.S. Broggi, Ying Cheng, David R. Spigel, Byoung Chul Cho +13 more
2025· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affunlabeled
A phase Ib/II open label study of IMU-131 HER2/Neu peptide vaccine plus cisplatin and either 5-fluorouracil or capecitabine chemotherapy in patients with HER2/Neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction.
Ursula Wiedermann, Anthony J. Good, Erika Garner‐Spitzer, Yee Chao, Iurie Bulat, Arunee Dechaphunkul +13 more
2019· article· en· Journal of Clinical Oncology· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affunlabeled
MicroRNA polymorphisms and esophageal cancer outcome.
Olusola Olusesan Faluyi, Lawson Eng, Xin Qui, Dangxiao Cheng, Daniel J. Renouf, Sharon Marsh +7 more
2013· article· en· Journal of Clinical Oncology· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
2
citations

How this was built: Screen · Findings · About